LYRA THERAPEUTICS announces additional data presentations FROM PHASE 2 LANTERN STUDY at the americal rhinologic society annual meeting
Significantly more patients with moderate/severe symptoms of chronic rhinosinusitis at baseline improved to mild/no symptoms at week 24 after treatment with LYR-210 (7500μg) compared to control The three cardinal symptoms composite score shown to correlate with the well-established…
Comments Off on LYRA THERAPEUTICS announces additional data presentations FROM PHASE 2 LANTERN STUDY at the americal rhinologic society annual meeting